<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40498936</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1726-4642</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>09</Day></PubDate></JournalIssue><Title>Revista peruana de medicina experimental y salud publica</Title><ISOAbbreviation>Rev Peru Med Exp Salud Publica</ISOAbbreviation></Journal><ArticleTitle>Clinical and microbiological characteristics of pediatric patients hospitalized for pneumococcal pneumonia before and after the introduction of pneumococcal conjugate vaccines.</ArticleTitle><Pagination><StartPage>63</StartPage><EndPage>69</EndPage><MedlinePgn>63-69</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.17843/rpmesp.2025.421.13847</ELocationID><Abstract><AbstractText>The clinical and microbiological characteristics of pneumococcal pneumonia in children hospitalized in Lima were analyzed, before and after the introduction of pneumococcal conjugate vaccines (PCV). We reviewed cases that occurred between 2006-2019, in the pre-PCV7 (2006-2008), post-PCV7 (2009-2011) and post-PCV13 (2016-2019) periods. Of 128 patients with positive cultures (92 blood and 36 pleural fluid), most were infants in the pre-PCV7 (77.1%) and post-PCV7 (43.3%) studies, while in the post-PCV13 study they were mostly preschoolers (62%). We found an increase in complicated pneumonia cases from 14.6% to 72% and an increase in serotype 19A (6.3% to 68%). The most frequent sequence type was ST320 (31 isolates). Resistance to penicillin and ceftriaxone was low (6% and 2%, respectively), although higher in empyema (21.4% and 14.3%, respectively). Resistance to azithromycin increased from 27% to 92%. Penicillin remains the antibiotic of choice for the treatment of uncomplicated pneumococcal pneumonia in Lima. Motivation for the study. Although studies on invasive pneumococcal disease have been conducted in Lima, the characteristics of pneumococcal pneumonia before and after the introduction of pneumococcal conjugate vaccines are unknown. Main findings. We found an increase in complicated pneumococcal pneumonia cases, particularly empyema and an increase in serotype 19A. Resistance to penicillin and ceftriaxone was found to be low; however, in cases of empyema, antibiotic resistance was higher. Public health implications. Penicillin or amoxicillin should continue to be prescribed for the empirical management of pneumococcal pneumonia; however, ceftriaxone is recommended for cases with empyema. Continued local monitoring of pneumococcal resistance and serotypes is recommended.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gomez</LastName><ForeName>Carolina A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0009-0005-4868-9841</Identifier><AffiliationInfo><Affiliation>Facultad de Medicina Humana &#xab;Alberto Hurtado&#xbb;, Universidad Peruana Cayetano Heredia, Lima, Per&#xfa;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzales</LastName><ForeName>Brayan E</ForeName><Initials>BE</Initials><Identifier Source="ORCID">0000-0002-3059-6736</Identifier><AffiliationInfo><Affiliation>Instituto de Medicina Tropical &#xab;Alexander von Humboldt&#xbb;, Universidad Peruana Cayetano Heredia, Lima, Per&#xfa;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez</LastName><ForeName>Roger A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0002-1906-9599</Identifier><AffiliationInfo><Affiliation>Instituto de Medicina Tropical &#xab;Alexander von Humboldt&#xbb;, Universidad Peruana Cayetano Heredia, Lima, Per&#xfa;.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Pediatr&#xed;a, Hospital Nacional Cayetano Heredia, Lima, Per&#xfa;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campos</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-1352-0606</Identifier><AffiliationInfo><Affiliation>Hospital Nacional Docente Madre-Ni&#xf1;o San Bartolom&#xe9;. Lima, Per&#xfa;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaparro</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><Identifier Source="ORCID">0009-0005-9158-5562</Identifier><AffiliationInfo><Affiliation>Facultad de Medicina Humana &#xab;Alberto Hurtado&#xbb;, Universidad Peruana Cayetano Heredia, Lima, Per&#xfa;.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Pediatr&#xed;a, Hospital Nacional Cayetano Heredia, Lima, Per&#xfa;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del &#xc1;guila</LastName><ForeName>Olguita</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-3085-0148</Identifier><AffiliationInfo><Affiliation>Servicio de Pediatr&#xed;a de Especialidades Cl&#xed;nicas, Hospital Nacional Edgardo Rebagliati Martins, Lima, Per&#xfa;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castillo</LastName><ForeName>Mar&#xed;a E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0003-2192-6235</Identifier><AffiliationInfo><Affiliation>Facultad de Medicina Humana &#xab;Alberto Hurtado&#xbb;, Universidad Peruana Cayetano Heredia, Lima, Per&#xfa;.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oficina de Epidemiolog&#xed;a, Instituto Nacional de Salud del Ni&#xf1;o, Lima, Per&#xfa;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saenz</LastName><ForeName>Andr&#xe9;s</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0004-6696-0116</Identifier><AffiliationInfo><Affiliation>Departamento de Pediatr&#xed;a, Hospital Nacional Daniel Alcides Carri&#xf3;n, Lima, Per&#xfa;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reyes</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><Identifier Source="ORCID">0009-0009-1433-1859</Identifier><AffiliationInfo><Affiliation>Servicio de Hospitalizaci&#xf3;n, Hospital de Emergencias Pedi&#xe1;tricas, Lima, Per&#xfa;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ochoa</LastName><ForeName>Theresa J</ForeName><Initials>TJ</Initials><Identifier Source="ORCID">0000-0002-3227-3906</Identifier><AffiliationInfo><Affiliation>Instituto de Medicina Tropical &#xab;Alexander von Humboldt&#xbb;, Universidad Peruana Cayetano Heredia, Lima, Per&#xfa;.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Pediatr&#xed;a, Hospital Nacional Cayetano Heredia, Lima, Per&#xfa;.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Caracter&#xed;sticas cl&#xed;nicas y microbiol&#xf3;gicas de pacientes pedi&#xe1;tricos hospitalizados por neumon&#xed;a neumoc&#xf3;cica antes y despu&#xe9;s de la introducci&#xf3;n de las vacunas conjugadas neumoc&#xf3;cicas.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Peru</Country><MedlineTA>Rev Peru Med Exp Salud Publica</MedlineTA><NlmUniqueID>101227566</NlmUniqueID><ISSNLinking>1726-4634</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022242">Pneumococcal Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018074">Vaccines, Conjugate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000069443">Heptavalent Pneumococcal Conjugate Vaccine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022242" MajorTopicYN="Y">Pneumococcal Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011018" MajorTopicYN="Y">Pneumonia, Pneumococcal</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018074" MajorTopicYN="N">Vaccines, Conjugate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069443" MajorTopicYN="Y">Heptavalent Pneumococcal Conjugate Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013296" MajorTopicYN="N">Streptococcus pneumoniae</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Se analizaron las caracter&#xed;sticas cl&#xed;nicas y microbiol&#xf3;gicas de neumon&#xed;a neumoc&#xf3;cica en ni&#xf1;os hospitalizados en Lima, antes y despu&#xe9;s de la introducci&#xf3;n de las vacunas neumoc&#xf3;cicas conjugadas (PCV). Se revisaron casos entre 2006-2019, en los periodos pre-PCV7 (2006-2008), post-PCV7 (2009-2011) y post-PCV13 (2016-2019). De 128 pacientes con cultivos positivos (92 de sangre y 36 de l&#xed;quido pleural), la mayor&#xed;a fueron lactantes en los estudios pre-PCV7 (77,1%) y post-PCV7 (43,3%), mientras que en el estudio post-PCV13 fueron mayoritariamente preescolares (62%). Se observ&#xf3; un aumento de neumon&#xed;as complicadas de 14,6% a 72% y un incremento del serotipo 19A (6,3% a 68%). El secuenciotipo m&#xe1;s frecuente fue ST320 (31 aislamientos). La resistencia a penicilina y ceftriaxona fue baja (6% y 2%, respectivamente), aunque mayor en empiema (21,4% y 14,3%, respectivamente). La resistencia a azitromicina se increment&#xf3; de 27% a 92%. La penicilina sigue siendo el antibi&#xf3;tico de elecci&#xf3;n para el tratamiento de neumon&#xed;a neumoc&#xf3;cica no complicada en Lima. Motivaci&#xf3;n para realizar el estudio. Si bien, en Lima se han llevado a cabo estudios sobre la enfermedad neumoc&#xf3;cica invasiva, se desconocen las caracter&#xed;sticas de neumon&#xed;a por neumococo antes y despu&#xe9;s de la introducci&#xf3;n de las vacunas neumoc&#xf3;cicas conjugadas. Principales hallazgos. Se encontr&#xf3; un aumento de neumon&#xed;a neumoc&#xf3;cica complicada, especialmente empiema y aumento del serotipo 19A. La resistencia a penicilina y ceftriaxona se mantiene baja; sin embargo, en casos de empiema, la resistencia antibi&#xf3;tica fue mayor. Implicancias en salud p&#xfa;blica. Se debe continuar indicando penicilina o amoxicilina para el manejo emp&#xed;rico de neumon&#xed;a neumoc&#xf3;cica; sin embargo, para casos con empiema se sugiere usar ceftriaxona. Se recomienda seguir monitorizando la resistencia y los serotipos de neumococo localmente.</AbstractText></OtherAbstract><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Se analizaron las caracter&#xed;sticas cl&#xed;nicas y microbiol&#xf3;gicas de neumon&#xed;a neumoc&#xf3;cica en ni&#xf1;os hospitalizados en Lima, antes y despu&#xe9;s de la introducci&#xf3;n de las vacunas neumoc&#xf3;cicas conjugadas (PCV). Se revisaron casos entre 2006-2019, en los periodos pre-PCV7 (2006-2008), post-PCV7 (2009-2011) y post-PCV13 (2016-2019). De 128 pacientes con cultivos positivos (92 de sangre y 36 de l&#xed;quido pleural), la mayor&#xed;a fueron lactantes en los estudios pre-PCV7 (77,1%) y post-PCV7 (43,3%), mientras que en el estudio post-PCV13 fueron mayoritariamente preescolares (62%). Se observ&#xf3; un aumento de neumon&#xed;as complicadas de 14,6% a 72% y un incremento del serotipo 19A (6,3% a 68%). El secuenciotipo m&#xe1;s frecuente fue ST320 (31 aislamientos). La resistencia a penicilina y ceftriaxona fue baja (6% y 2%, respectivamente), aunque mayor en empiema (21,4% y 14,3%, respectivamente). La resistencia a azitromicina se increment&#xf3; de 27% a 92%. La penicilina sigue siendo el antibi&#xf3;tico de elecci&#xf3;n para el tratamiento de neumon&#xed;a neumoc&#xf3;cica no complicada en Lima.</AbstractText></OtherAbstract><CoiStatement><b>Conflicts of interest.:</b> None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>11</Day><Hour>22</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>11</Day><Hour>22</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>11</Day><Hour>14</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>3</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40498936</ArticleId><ArticleId IdType="pmc">PMC12176018</ArticleId><ArticleId IdType="doi">10.17843/rpmesp.2025.421.13847</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pneumonia in children. World Health Organization;  [1 de junio de 2023].  Internet. Disponible en:  https://www.who.int/news-room/fact-sheets/detail/pneumonia
.</Citation></Reference><Reference><Citation>Wahl B, Sharan A, Deloria Knoll M, Kumar R, Liu L, Chu Y, et al. National, regional, and state-level burden of streptococcus pneumoniae and haemophilus influenzae type b disease in children in India: Modelled estimates for 2000-15. The Lancet Glob Health. 2019;7(6) doi: 10.1016/s2214-109x(19)30081-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2214-109x(19)30081-6</ArticleId><ArticleId IdType="pmc">PMC6527518</ArticleId><ArticleId IdType="pubmed">31097277</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministerio de Salud  . Norma T&#xe9;cnica de Salud que establece el esquema nacional de vacunaci&#xf3;n. NTS N&#xb0;116-2016. MINSA; 2016.  [10 de agosto de 2018].  Internet. Disponible en:  https://cdn.www.gob.pe/uploads/document/file/3823311/Norma%20T&#xe9;cnica%20de%20Salud.pdf?v=1668009871
.</Citation></Reference><Reference><Citation>Gonzales BE, Mercado EH, Pinedo-Bardales M, Hinostroza N, Campos F, Chaparro E, et al. Increase of macrolide-resistance in streptococcus pneumoniae strains after the introduction of the 13-valent pneumococcal conjugate vaccine in Lima, Peru. Front Cell Infect Microbiol. 2022;12 doi: 10.3389/fcimb.2022.866186.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.866186</ArticleId><ArticleId IdType="pmc">PMC9125093</ArticleId><ArticleId IdType="pubmed">35615398</ArticleId></ArticleIdList></Reference><Reference><Citation>Ochoa TJ, Egoavil M, Castillo ME, Reyes I, Chaparro E, Silva W. Invasive pneumococcal diseases among hospitalized children in Lima, Peru. Rev Panam Salud Publica. 2010;28(2):121&#x2013;127. doi: 10.1590/s1020-49892010000800008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s1020-49892010000800008</ArticleId><ArticleId IdType="pubmed">20963279</ArticleId></ArticleIdList></Reference><Reference><Citation>Luna-Muschi A, Castillo-Tokumori F, Deza MP, Mercado EH, Egoavil M, Sedano K, et al. Invasive pneumococcal disease in hospitalised children from Lima, Peru before and after introduction of the 7-valent conjugated vaccine. Epidemiol Infect. 2019;147 doi: 10.1017/s0950268819000037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/s0950268819000037</ArticleId><ArticleId IdType="pmc">PMC6518591</ArticleId><ArticleId IdType="pubmed">30869013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ochoa TJ, Del &#xc1;guila O, Reyes I, Chaparro E, Castillo ME, Campos F. Streptococcus pneumoniae serotype 19A in hospitalized children with invasive pneumococcal disease after the introduction of conjugated vaccines in Lima, Peru. J Infect Public Health. 2023;17(1):44&#x2013;50. doi: 10.1016/j.jiph.2023.10.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2023.10.047</ArticleId><ArticleId IdType="pubmed">37992433</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical and Laboratory Standards Institute, (CLSI Performance standards for antimicrobial susceptibility testing M100. (29) 2019;39</Citation></Reference><Reference><Citation>Tran Quang K, Tran Do H, Pham Hung V, Nguyen Vu T, Tran Xuan B, Larsson M, et al. Study on the co-infection of children with severe community-acquired pneumonia. Pediatr Int. 2021;64(1) doi: 10.1111/ped.14853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ped.14853</ArticleId><ArticleId IdType="pubmed">34661955</ArticleId></ArticleIdList></Reference><Reference><Citation>Fletcher MA, Schmitt H-J, Syrochkina M, Sylvester G. Pneumococcal empyema and complicated pneumonias Global trends in incidence, prevalence, and serotype epidemiology. Eur J of Clin Microbiol Infect Dis. 2014;33(6):879&#x2013;910. doi: 10.1007/s10096-014-2062-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-014-2062-6</ArticleId><ArticleId IdType="pmc">PMC4110404</ArticleId><ArticleId IdType="pubmed">24563274</ArticleId></ArticleIdList></Reference><Reference><Citation>Adebanjo TA, Pondo T, Yankey D, Hill HA, Gierke R, Apostol M, et al. Pneumococcal conjugate vaccine breakthrough infections: 2001-2016. Pediatrics. 2020;145(3) doi: 10.1542/peds.2019-0836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2019-0836</ArticleId><ArticleId IdType="pmc">PMC7055927</ArticleId><ArticleId IdType="pubmed">32054822</ArticleId></ArticleIdList></Reference><Reference><Citation>Strachan R, Homaira N, Beggs S, Bhuiyan MU, Gilbert GL, Lambert SB. Assessing the impact of the 13 valent pneumococcal vaccine on Childhood Empyema in Australia. Thorax. 2021;76(5):487&#x2013;493. doi: 10.1136/thoraxjnl-2020-216032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-216032</ArticleId><ArticleId IdType="pubmed">33504566</ArticleId></ArticleIdList></Reference><Reference><Citation>Guti&#xe9;rrez-Tobar IF, Londo&#xf1;o-Ruiz JP, Mari&#xf1;o-Drews C, Beltr&#xe1;n-Higuera S, Camacho-Moreno G, Leal-Castro AL. Epidemiological characteristics and serotype distribution of culture-confirmed pediatric pneumococcal pneumonia before and after PCV 10 introduction, a Multicenter Study in Bogota, Colombia, 2008-2019. Vaccine. 2022;40(20):2875&#x2013;2883. doi: 10.1016/j.vaccine.2022.03.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.03.022</ArticleId><ArticleId IdType="pubmed">35396166</ArticleId></ArticleIdList></Reference><Reference><Citation>Vigilancia de Laboratorio comportamiento de streptococcus pneumoniae serotipos 13 y 19A en Chile, a&#xf1;os 2007-2015 - ISPCH. Instituto de Salud P&#xfa;blica de Chile; 2016.  [2023 Sept 15].  Internet. Disponible en: from:  https://www.ispch.cl/sites/default/files/Boletin%20S.pneumoniae%2019A%20y%203.pdf
.</Citation></Reference><Reference><Citation>Gagetti P, Lo SW, Hawkins PA, Gladstone RA, Regueira M, Faccone D, et al. Population genetic structure, serotype distribution and antibiotic resistance of streptococcus pneumoniae causing invasive disease in children in Argentina. Microb Genom. 2021;7(9) doi: 10.1099/mgen.0.000636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/mgen.0.000636</ArticleId><ArticleId IdType="pmc">PMC8715423</ArticleId><ArticleId IdType="pubmed">34586054</ArticleId></ArticleIdList></Reference><Reference><Citation>Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of streptococcus pneumoniae causing invasive disease in children in the post-PCV ERA: A systematic review and meta-analysis. PLoS One. 2017;12(5) doi: 10.1371/journal.pone.0177113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0177113</ArticleId><ArticleId IdType="pmc">PMC5423631</ArticleId><ArticleId IdType="pubmed">28486544</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohanty S, Feemster K, Yu KC, Watts JA, Gupta V. Trends in Streptococcus pneumoniae Antimicrobial Resistance in US Children: A Multicenter Evaluation. Open Forum Infect Dis. 2023;10(3) doi: 10.1093/ofid/ofad098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofad098</ArticleId><ArticleId IdType="pmc">PMC10034583</ArticleId><ArticleId IdType="pubmed">36968964</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandoval MM, Ruvinsky S, Palermo MC, Alconada T, Brizuela ME, Wierzbicki ER, et al. Antimicrobial resistance of streptococcus pneumoniae from invasive pneumococcal diseases in Latin American countries: A systematic review and meta-analysis. Front Public Health. 2024;12 doi: 10.3389/fpubh.2024.1337276.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2024.1337276</ArticleId><ArticleId IdType="pmc">PMC10839967</ArticleId><ArticleId IdType="pubmed">38317800</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida SC, Lo SW, Hawkins PA, Gladstone RA, Cassiolato AP, Klugman KP, et al. Genomic surveillance of invasive streptococcus pneumoniae isolates in the period pre-PCV10 and post-PCV10 introduction in Brazil. Microb Genom. 2021;7(10) doi: 10.1099/mgen.0.000635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/mgen.0.000635</ArticleId><ArticleId IdType="pmc">PMC8627213</ArticleId><ArticleId IdType="pubmed">34609274</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28599870</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2173-5743</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Season>Sep-Oct</Season></PubDate></JournalIssue><Title>Reumatologia clinica</Title><ISOAbbreviation>Reumatol Clin (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Osteoarticular infections caused by Streptococcus pneumoniae since authorization of conjugate vaccines.</ArticleTitle><Pagination><StartPage>e62</StartPage><EndPage>e65</EndPage><MedlinePgn>e62-e65</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.reuma.2017.05.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1699-258X(17)30121-3</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arrizabalaga</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Interna, Hospital Son Ll&#xe0;tzer, Palma de Mallorca, Espa&#xf1;a. Electronic address: marrizab@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borjas</LastName><ForeName>Yolanda</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Interna, Hospital Son Ll&#xe0;tzer, Palma de Mallorca, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pe&#xf1;aranda</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Interna, Hospital Universitario Son Espases, Palma de Mallorca, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garau</LastName><ForeName>Margarita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Microbiolog&#xed;a, Hospital Son Ll&#xe0;tzer, Palma de Mallorca, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ru&#xed;z de Gopegui</LastName><ForeName>Enrique</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Servicio de Microbiolog&#xed;a, Hospital Universitario Son Espases, Palma de Mallorca, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Payeras</LastName><ForeName>Antoni</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Interna, Hospital Son Ll&#xe0;tzer, Palma de Mallorca, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Afectaci&#xf3;n osteoarticular por Streptococcus pneumoniae tras la autorizaci&#xf3;n de las vacunas conjugadas.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Reumatol Clin (Engl Ed)</MedlineTA><NlmUniqueID>101717526</NlmUniqueID><ISSNLinking>2173-5743</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018074">Vaccines, Conjugate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001850" MajorTopicYN="Y">Bone Diseases, Infectious</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007592" MajorTopicYN="N">Joint Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011008" MajorTopicYN="Y">Pneumococcal Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018074" MajorTopicYN="N">Vaccines, Conjugate</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28599870</ArticleId><ArticleId IdType="doi">10.1016/j.reuma.2017.05.003</ArticleId><ArticleId IdType="pii">S1699-258X(17)30121-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28318182</PMID><DateCompleted><Year>2018</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2018</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1668-3501</ISSN><JournalIssue CitedMedium="Internet"><Volume>115</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Archivos argentinos de pediatria</Title><ISOAbbreviation>Arch Argent Pediatr</ISOAbbreviation></Journal><ArticleTitle>Pneumococcal meningitis in Cantabria (Spain) in the pneumococcal conjugate vaccine era (2001-2015).</ArticleTitle><Pagination><StartPage>160</StartPage><EndPage>164</EndPage><MedlinePgn>160-164</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5546/aap.2017.eng.160</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To analyze the characteristics of pneumococcal meningitis in children &#x2264; 14 years old following the market introduction of pneumococcal conjugate vaccines in our community.</AbstractText><AbstractText Label="METHODS">Retrospective study of pneumococcal meningitis cases with a two-period analysis: pre-13-valent pneumococcal conjugate vaccine (PCV13) (2001-2010) and post-PCV13 (2010-2015). Patient demographic and clinical data, and microbiological data were collected.</AbstractText><AbstractText Label="RESULTS">Eighteen cases were diagnosed. The mean incidence in the pre-PCV13 period was 2.3/100 000, which reduced to 0.5/100 000 after the PCV13 introduction. The most commonly identified serotypes were 6A and 10A (pre-PCV13); 6B and 15B (post-PCV13, only 2 cases). Out of 18 patients, 13 were admitted to the intensive care unit. All cases were treated with cefotaxime, and 14/18 received dexamethasone. Six patients survived with sequelae, and 1 died.</AbstractText><AbstractText Label="CONCLUSION">A major reduction has been observed in the incidence of pneumococcal meningitis since the introduction of the PCV13 to the market, so an even greater reduction is expected following its systematic introduction.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Escart&#xed;n</LastName><ForeName>Esther</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Servicio de Pediatr&#xed;a, Hospital Universitario Marqu&#xe9;s de Valdecilla, Santander (Cantabria), Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angulo L&#xf3;pez</LastName><ForeName>Itziar</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Servicio de Microbiolog&#xed;a, Hospital Universitario Marqu&#xe9;s de Valdecilla, Santander (Cantabria), Espa&#xf1;a. itzupitzu@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ots Ruiz</LastName><ForeName>Elsa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Intensiva. Unidad de Cuidados Intensivos Pedi&#xe1;tricos, Hospital Universitario Marqu&#xe9;s de Valdecilla, Santander (Cantabria), Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez-Mart&#xed;nez</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Servicio de Microbiolog&#xed;a, Hospital Universitario Marqu&#xe9;s de Valdecilla, Santander (Cantabria), Espa&#xf1;a.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Biolog&#xed;a Molecular, Facultad de Medicina, Universidad de Cantabria, Santander (Cantabria), Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabero P&#xe9;rez</LastName><ForeName>Mar&#xed;a J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Servicio de Pediatr&#xed;a, Hospital Universitario Marqu&#xe9;s de Valdecilla, Santander (Cantabria), Espa&#xf1;a.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Ciencias M&#xe9;dicas y Quir&#xfa;rgicas, Facultad de Medicina, Universidad de Cantabria, Santander (Cantabria), Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Meningitis neumoc&#xf3;cica en Cantabria (Espa&#xf1;a) en la era de las vacunas conjugadas antineumoc&#xf3;cicas (2001-2015).</VernacularTitle></Article><MedlineJournalInfo><Country>Argentina</Country><MedlineTA>Arch Argent Pediatr</MedlineTA><NlmUniqueID>0372460</NlmUniqueID><ISSNLinking>0325-0075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C538862">13-valent pneumococcal vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022242">Pneumococcal Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008586" MajorTopicYN="N">Meningitis, Pneumococcal</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022242" MajorTopicYN="Y">Pneumococcal Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Analizar las caracter&#xed;sticas de la meningitis neumoc&#xf3;cica en &#x2264; 14 a&#xf1;os tras la comercializaci&#xf3;n de vacunas antineumoc&#xf3;cicas conjugadas en nuestra comunidad.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Streptococcus pneumoniae</Keyword><Keyword MajorTopicYN="N">immunization</Keyword><Keyword MajorTopicYN="N">meningitis</Keyword><Keyword MajorTopicYN="N">pediatrics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28318182</ArticleId><ArticleId IdType="doi">10.5546/aap.2017.eng.160</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">27986203</PMID><DateCompleted><Year>2018</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2212-1102</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2016</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Value in health regional issues</Title><ISOAbbreviation>Value Health Reg Issues</ISOAbbreviation></Journal><ArticleTitle>Estimaci&#xf3;n de la Relaci&#xf3;n Costo-Efectividad de las Vacunas Neumoc&#xf3;cicas Conjugadas Prevenar-13 y Synflorix&#xae;, Utilizadas en Los Programas de Vacunaci&#xf3;n de Poblaci&#xf3;n Infantil Mexicana.</ArticleTitle><Pagination><StartPage>76</StartPage><EndPage>84</EndPage><MedlinePgn>76-84</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vhri.2016.07.009</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2212-1099(16)30035-8</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To estimate the cost effectiveness associated with the use of pneumococcal conjugated vaccines, Prevenar-13 and Synflorix&#xae;, in the Mexican pediatric population.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The cost-effectiveness ratio of instrumenting vaccination programs based upon the use of Prevenar-13 and Synflorix&#xae; in the Mexican pediatric population was estimated by using a Markov's simulation model. The robustness of the conclusions reached on cost-effectiveness for both vaccines was assayed through an univariate and probabilistic sensitivity analysis that included all of the parameters considered by the model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Synflorix&#xae; was dominant over Prevenar-13 in the cost-utility analysis; the former generated more quality-adjusted life years at a lower cost and with a lower incremental cost-utility ratio. Based on the cost-effective analysis, Prevenar-13 generated more life years gained but at a higher cost. The use of Prevenar-13 originated a higher incremental cost-effectiveness ratio and, therefore, it was not cost-effective as compared with Synflorix&#xae;.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Even though the simulations for Prevenar-13 and Synflorix&#xae; revealed both of them to be cost-effective when used to instrument pediatric vaccination campaigns in Mexico, Synflorix&#xae; had a better cost-utility/effectiveness profile. In addition, although Prevenar-13 and Synflorix&#xae; produced equivalent health outcomes, the overall analysis predicted that Synflorix&#xae; would save 360 million Mexican pesos, as compared with Prevenar-13.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>G&#xf3;mez</LastName><ForeName>Jorge A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline Vacunas, Buenos Aires, Argentina. Electronic address: Jorge.A.Gomez@gsk.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villase&#xf1;or-Sierra</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratorio de Microbiolog&#xed;a Molecular, Centro de Investigaci&#xf3;n Biom&#xe9;dica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguilar</LastName><ForeName>Gerardo Mart&#xed;nez</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Jefatura de Prestaciones M&#xe9;dicas, Instituto Mexicano del Seguro Social, Durango, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manjarrez</LastName><ForeName>Roberto Carre&#xf1;o</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline Vacunas, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cervantes-Apolinar</LastName><ForeName>Mar&#xed;a Y</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline Vacunas, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>12</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Value Health Reg Issues</MedlineTA><NlmUniqueID>101592642</NlmUniqueID><ISSNLinking>2212-1099</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000069443">Heptavalent Pneumococcal Conjugate Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C547294">PHiD-CV vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022242">Pneumococcal Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018074">Vaccines, Conjugate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069443" MajorTopicYN="N">Heptavalent Pneumococcal Conjugate Vaccine</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N">Mexico</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011008" MajorTopicYN="N">Pneumococcal Infections</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022242" MajorTopicYN="N">Pneumococcal Vaccines</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019057" MajorTopicYN="Y">Quality-Adjusted Life Years</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013296" MajorTopicYN="N">Streptococcus pneumoniae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018074" MajorTopicYN="N">Vaccines, Conjugate</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cost effectiveness</Keyword><Keyword MajorTopicYN="N">Mexico</Keyword><Keyword MajorTopicYN="N">Streptococcus pneumoniae</Keyword><Keyword MajorTopicYN="N">pediatric population</Keyword><Keyword MajorTopicYN="N">prevention of pneumococcal disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27986203</ArticleId><ArticleId IdType="doi">10.1016/j.vhri.2016.07.009</ArticleId><ArticleId IdType="pii">S2212-1099(16)30035-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>